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Abstract: Asthma is a chronic lung disease affecting people of all ages worldwide, and it 
frequently begins in childhood. Because of its chronic nature, it is characterized by pathological 
manifestations, including airway inflammation, remodeling, and goblet cell hyperplasia. Current 
therapies for asthma, including corticosteroids and beta-2 adrenergic agonists, are directed 
toward relieving the symptoms of the asthmatic response, with poor effectiveness against the 
underlying causes of the disease. Asthma initiation and progression depends on the T helper 
(Th) 2 type immune response carried out by a complex interplay of cytokines, such as interleukin 
(IL) 4, IL5, and IL13, and the signal transducer and activator of transcription 6. Much of the data 
resulting from different laboratories support the role of poly(ADP-ribose) polymerase (PARP) 1 
and PARP14 activation in asthma. Indeed, PARP enzymes play key roles in the regulation and 
progression of the inflammatory asthma process because they affect the expression of genes and 
chemokines involved in the immune response. Consistently, PARP inhibition achievable either 
upon genetic ablation or by using pharmacological agents has shown a range of therapeutic 
effects against the disease. Indeed, in the last two decades, several preclinical studies highlighted 
the protective effects of PARP inhibition in various animal models of asthma. PARP inhibi-
tors showed the ability to reduce the overall lung inflammation acting with a specific effect on 
immune cell recruitment and through the modulation of asthma-associated cytokines production. 
PARP inhibition has been shown to affect the Th1–Th2 balance and, at least in some aspects, the 
airway remodeling. In this review, we summarize and discuss the steps that led PARP inhibition 
to become a possible future therapeutic strategy against allergic asthma.
Keywords: allergic airway disease, PARP1, PARP14, remodeling, STAT6, Th1–Th2 balance, 
Th2 response
Introduction
More than five decades after the discovery of the poly(ADP-ribosyl)ation pathway,1 
the potential benefits of treating some human life-threatening diseases, such as cancer 
and serious cardiovascular conditions, with inhibitors of that enzymatic system are a 
promising reality. In fact, many poly(ADP-ribose) polymerase (PARP) inhibitors have 
been enrolled in clinical trials as a combination therapy for several types of cancer, 
and many of these were licensed by the Food and Drug Administration (FDA) and/or 
the European Medicines Agency (EMA). To name a few, olaparib and rucaparib are 
licensed by FDA against recurrent ovarian cancer. Olaparib is also licensed by EMA 
as a maintenance therapy agent in patients displaying germline or somatic BRCA 
mutations.2 Finally, more than 10 years of clinical PARP research, and even more of 
preclinical phase, have been translated into promising therapies for patients.3,4 Starting 
from these exciting results, research in the PARP field is evolving to uncover the roles 
of this family of enzymes in multiple biological and pathological pathways related to 
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many diseases, with the aim to discover new therapeutic 
approaches in combination or as single therapies.5
Chronic airway inflammatory diseases, such as asthma, 
are life-threatening conditions that impact on the quality 
of life and health care systems. Globally, over 300 million 
people are affected by asthma, and the incidence of the disease 
is increasing, affecting 1 in 10 children and 1 in 12 adults.6–8 
Individuals suffering from this condition widely range from 
teenage children to elderly people. According to World 
Health Organization, asthma is annually responsible for over 
180,000 deaths.9 Allergic asthma is a complex syndrome 
resulting from the interplay of genetic and environmental 
factors. It is characterized by three essential modifications 
of the airway features: inflammation, hyperresponsiveness, 
and remodeling.7,8,10 These manifestations lead to repeated 
breathlessness attacks, wheezing, coughing, and chest tight-
ness often occurring after exposure to allergens, pollutants, 
infections, or drugs.7,11 Airway inflammation is a protective 
response to cellular injuries and represents also the main 
feature of asthma. However, when this beneficial response 
occurs in an uncontrolled way, it causes excessive cellular 
and tissue damage through the release of reactive oxygen 
species (ROS). These events result in chronic inflammation 
and destruction of normal tissue, enhancing DNA damage.12,13 
Considering this mechanism, PARP enzymes (PARPs) have 
been shown to mediate inflammation in a wide range of 
animal models of diseases.13,14
Allergic asthma can be controlled by a combination of a 
corticosteroid (an anti-inflammatory agent) and a short- or 
long-acting beta-2 adrenergic agonist. Unfortunately, 10% 
of patients do not respond to these therapies, and even if 
those drugs are effective in controlling symptoms, they do 
not impact the progressive airway remodeling.15 Hence, new 
therapeutic approaches are needed.
In the last two decades, several studies highlighted the 
protective effects of PARPs inhibition in various animal 
models of asthma. The focus of this review is centered on the 
current understanding of the PARP inhibition as a possible 
new therapeutic approach to counteract human asthma.
PARPs involvement in allergic 
airway inflammation: evidences 
from studies on humans
Previous studies have shown a genetic correlation of PARPs 
with asthma and allergic rhinitis in humans. Concerning one 
of the PARP isoenzymes (PARP1), Tezcan et al16 analyzed 
122 Turkish subjects affected by stable asthma in com-
parison with 180 normal controls coming from the same 
geographic region and also identified PARP1 polymorphism 
by performing polymerase chain reaction-based restriction 
analyses. The results of this study showed a positive cor-
relation between wild-type PARP1 762 V allele and risk of 
developing asthma, which was indeed five times higher than 
in subjects lacking the allele. In contrast, PARP1 762 AA 
genotype conferred a 3.4-fold risk reduction.16 The object of 
another study is to investigate whether a single-nucleotide 
polymorphism of the PARP1 gene promoter was associated 
with a genetic susceptibility to allergic rhinitis in 110 subjects 
affected by this disease and 130 used as controls. In this study, 
the heterozygous genotype of the polymorphism promoter 
(−1,672) was found to be significantly associated with sus-
ceptibility to allergic rhinitis.17
Recently, the relevance and significance of these studies 
have been supported by the evidence described by Ghonim 
et al18 that the enzyme is activated in cells or tissues of 
asthmatic humans. To do so, they compared lung specimens 
and peripheral blood mononuclear cells of six asthmatic 
patients with those of four normal subjects. However, the 
validity of these results is reduced by the few number of 
human samples screened.
Anyway, these data point out, on the one hand, a close link 
between PARPs and allergic airway inflammation diseases 
in humans and, on the other hand, suggest that PARP1 gene 
polymorphism may represent one of the factors conferring 
protection or susceptibility to asthma and allergic rhinitis.
PARPs cellular functions: focus on 
inflammation
PARPs is a family of 18 enzymes capable of cleaving the 
ADP-ribose moiety of NAD+ and carrying it onto several 
nuclear substrates in a monomeric or, most likely, an oli-
gomeric form.19 This posttranslational protein modification 
is named ADP-ribosylation reaction. A new nomenclature, 
based on the type of the enzymatic reaction catalyzed and 
the PARP structural features, has been proposed for this 
family of enzymes. Hence, the PARP family members 
are now referred to as ADP-ribosyltransferase diphtheria 
toxin-like (ARTD) family of proteins.20 However, in this 
review, the old, more common, “PARP” nomenclature has 
been used.
The first PARP enzyme discovered was PARP1 (ARTD1) 
enzyme, whose enzymatic action is strongly activated 
by single DNA strand breaks.1 At the beginning, PARP1 
function was mainly associated with the repair mechanism 
of damaged DNA.1 Afterward, PARP1 and other PARP 
enzymes were recognized to be involved also in many other 
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important cellular functions such as chromatin remodeling, 
cell differentiation, cell death or proliferation, and gene 
expression.14 The pleiotropic effects of these enzymes are 
mediated through the modification of the physicochemical 
properties of the recipient molecules. This modification is 
caused by the long anionic chains attached to the glutamate 
residues of different substrates and consisting of a maximum 
of 250 ADP-ribose monomers (PAR).21 PARP1 itself, which 
is responsible for about 90% of the total cellular poly ADP-
ribosylation activities, is poly ADP-ribosylated together with 
histones, nuclear repair enzymes, and transcription factors.22 
PARylation is a transient protein modification, as the polymer 
is rapidly split into ADP-ribose monomers and polymers by 
a poly(ADP-ribose) glycohydrolase.23 Free polymers also 
function as signaling molecules by attaching themselves to 
PAR binding motives present in various proteins.24 Indeed, 
PARylation is a multifunctional regulatory mechanism that 
is implicated in various cellular functions.25,26 In the last 
decade, several data highlighted the complex role of PARP1 
in the modulation of gene expression. PARP1-dependent 
transcriptional regulation may be ascribable to histone modi-
fication and change in chromatin composition, which in turn 
could facilitate gene transcription.27–29 For a long time, several 
studies using PARP inhibitors demonstrated the pivotal role 
of PARP1 in inflammation.21,25
Inflammation processes are associated with high levels 
of oxidative stress. ROS are produced by a mitochondrial 
respiratory chain dysfunction, by activation of NADPH 
oxidase, and mostly by inducible nitric oxide synthase 
(iNOS) expression.30 It is worth mentioning that several 
cytokines and chemokines, secreted by the immunocom-
petent cells infiltrated at the inflammation site, elicit iNOS 
induction.31 In the tissue, iNOS generates also superoxide 
besides a high amount of nitric oxide; these two free radicals 
interact with each other to form the potent oxidant molecule 
peroxynitrite.32 Among the ROS and nitrogen species, 
peroxynitrite is the most harmful agent inducing deep injuries 
on lipids, proteins, and DNA.33 When peroxynitrite attacks 
the sugar phosphate backbone, it results in DNA strand 
breaks33,34 that elicit tissue cytotoxicity by triggering PARP 
activation.35 While apoptosis is a typical consequence of 
low to moderate peroxynitrite concentrations, the exposure 
of cells to increasing concentrations of the oxidant has been 
associated with broad necrosis.36,37 Concerning cell death, it 
has been known for a long time that, after intense inflam-
mation stimuli, the overactivation of PARP1 causes an 
intracellular depletion of its NAD+ substrate. This effect is 
accompanied by a decrease of the cellular energy level and 
a consequent induction of necrosis.38 Recently, an interest-
ing study by Fouquerel et al39 demonstrated that PARP1 can 
induce cell necrosis in response to high level of DNA strand 
breaks through a different mechanism. The first glycolytic 
enzyme hexokinase 1, which is primarily associated with 
the outer mitochondrial membrane, is ADP-ribosylated 
after DNA damage and translocated to the cytosol with 
a concomitant loss of its enzymatic activity. Indeed, the 
block of the glycolytic pathway observed after induction 
of DNA strand breaks can be ascribable to hexokinase 1 
inactivation. Thus, the direct glycolysis inhibition, more than 
NAD+ depletion, could be responsible for the cell necrosis 
occurring in DNA-damaged cells.39 Moreover, some sirtuin 
members have been shown to play an important role in cell 
survival/death. NAD+ depletion, mediated by PARP1 activa-
tion in response to oxidative DNA damage, inhibits sirtuin1 
deacetylase activity. In this context, the increase of PARP1 
activity triggers the release of the apoptosis-inducing factor 
from mitochondria and causes apoptosis through a caspase-
independent pathway.40,41 In addition, the PAR polymer itself 
was shown to work as a signal, eliciting an unusual form of 
cell death named parthanatos.42
Accordingly, PARP1 enzyme, when fully activated, is 
involved in several types of cell death: necrosis, parthanatos, 
and apoptosis caused by both caspase-dependent and caspase-
independent pathways.41,43
The nuclear factor-kB (NF-kB) is the master tran-
scriptional promoter of inflammatory mediators, such as 
cytokines, chemokines, adhesion molecules, and iNOS.44 
Moreover, NF-kB is a molecule signaling the cell redox state 
because it is activated by ROS.45 Thus, the link between free 
radical damage, PARP1 and NF-kB activity, in the inflam-
mation context is demonstrated.45–47 Because PARP1 is a 
sensor of genotoxic stress, a PARP1-deficient mouse cell 
model has been used to investigate the mechanism whereby 
DNA damage induces NF-kB activation.48 Stilmann et al48 
reported that the PARylation of PARP1 triggers a cascade 
of events resulting in NF-kB nuclear translocation and 
activation. These events are accompanied by the assembly 
of PARP1 in a multiprotein complex where protein–protein 
interactions between PARP1, inhibitor kB kinase, and other 
proteins, but not NF-kB subunits themselves, are needed. 
On the contrary, Hassa et al49 showed that a direct interac-
tion between PARP1 and NF-kB subunits is required to 
achieve the full NF-kB activation. This result demonstrates 
that PARP1 acts as an NF-kB coactivator through protein–
protein interaction, independently of its enzyme activity.49 
In a different way, by using a macrophage murine model, 
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Liu et al50 showed a direct PARylation of the p65 NF-kB 
subunit and a consequent NF-kB activation. Accordingly, 
Zerfaoui et al51 demonstrated that PARylation of p65 NF-kB 
subunit elicits the nuclear retention of this transcription factor 
by decreasing its nuclear protein export. In conclusion, all 
data support the evidence that PARP1 elicits the transcription 
of several inflammatory genes by triggering NF-kB activa-
tion, although through different mechanisms.
In addition, PARP1 also modulates the activity of other 
transcription factors: activator protein 1, regulating cytok-
ines production, Th differentiation,52 and the nuclear factor 
of activated T cells, playing a pivotal role in the regulation 
of T cell functions.53,54 These, besides NF-kB, are important 
inflammatory mediators.
For all these reasons, PARP1 inhibition could overcome 
inflammation because of multiple molecular events. For 
an overview of the effects of PARP inhibition or deletion 
occurring in different types of inflammatory diseases, see 
the reviews by Berger et al14 and Cuzzocrea.47
As concerning, other PARP family members beyond 
PARP1, PARP2 (ARTD2), and PARP3 (ARTD3) are also 
activated by DNA strand breaks. They are the only members 
of this family being DNA damage-dependent enzymes.55 
Interestingly, both caspase 3 and caspase 8 cleave PARP2, 
suggesting that PARP2 may also be involved in modulating 
cellular necrosis/apoptosis.56 PARP2 knockdown reduces 
inflammation in interleukin (IL)10-deficient mouse models 
of chronic colitis,57 whereas no data connecting PARP2 or 
PARP3 to asthma have been found so far.
Many studies showed that PARP14 (ARTD8) is involved 
in transcription, signal transduction pathways, and cytoskel-
eton regulation.58 PARP14 is enzymatically active by cata-
lyzing mono-ADP ribosylation and belongs to a subfamily 
that contains repeats of a domain found in the nonhistone-
like region of a histone macro-H2A variant.59 Although the 
macrodomains of the macro-H2A histone participate in 
gene silencing,60 the PARP14 macrodomains interact with 
the signal transducer and activator of transcription (STAT)6 
by increasing the IL4-elicited gene expression.59 By the way, 
the PARP14-elicited transcriptional activation mechanism 
will be analyzed in the following section.
Mechanisms involving PARP family 
members in immune system and 
allergic asthma
Many years ago, we demonstrated that PARP1 gene expres-
sion, low in human resting T lymphocytes, rapidly increases 
after activation and 12-O-tetradecanoylphorbol-13-acetate 
(TPA)-induced differentiation of human T cells.61,62 In 
another study, we measured gene expression and the activity 
levels of PARP1 in 17 rat tissues. Our data demonstrated 
the presence of higher levels of PARP1 in rat thymus com-
pared to the other tissues but testis.63 Indeed, the induction 
of PARP1 gene transcription, together with the increase in 
PARP1 protein level and activity, suggested a functional role 
of this enzyme in the immune system.61–64
At least two members of this family, PARP1 and PARP14, 
have already been demonstrated to play an important role in 
allergic inflammatory diseases, as it is asthma.
Saenz et al65 demonstrated that PARP1 regulates the 
expression of a large number of genes, including those 
coding for chemokines and cytokines in T cells. T cells 
deriving from PARP deficiency (PARP1−/− mice) showed 
an increased expression of Th1 cytokines, interferon γ, 
and chemokine (C–C motif) ligands (CCLs) 4 and 9 and 
decreased production of IL4.65 According to the study by 
Rosado et al,66 naive cluster of differentiation (CD)4+ cells 
from PARP1 knockout mice generates less IL4 and expresses 
GATA3 mRNA at a lower level than wild-type mice cells, 
even under Th2 stimulation. Nasta et al67 reported that 
PARP1−/− mice show an increased number of forkhead box 
P3+ (FoxP3+) regulatory T (Treg) cells in thymus and in 
peripheral lymphatic organ displaying a normal phenotype. 
The molecular mechanism underlying the link between Treg 
cells and PARP1 was investigated by Zhang et al.68 They 
demonstrated that PARP1 downregulates the expression 
of transforming growth factor (TGF)βI/II receptors either 
as a function of its enzymatic activity or independently by 
aging as a transcription corepressor. During an inflamma-
tory reaction, the differentiation of naive CD4+ cells toward 
inducible Treg cells is inhibited by PARP1 activation. This 
effect depends on the decreasing sensitivity of CD4+ cells to 
TFGβ that blocks the Treg development. PARP1 inhibition 
or depletion reverts this inhibitory effect by increasing TGFβ 
receptors and, consequently, FoxP3+ gene expression, which 
is an essential regulator of Treg differentiation.68
Th17 cells play a pivotal role in induction and propagation 
of autoimmunity because they are defined by their ability to 
produce some cytokines, such as IL17A, IL17F, and IL22.69 
They were also shown to play a role in neutrophil recruit-
ment and airway resistance in patients affected by asthma.70 
Conflicting data have been reported concerning the effects 
of PARP1 inhibition/deletion in IL17 production.71 Zhang 
et al68 reported increased levels of IL17 in PARP1−/− mice, 
in comparison with the study by Nasta et al67 that showed 
no change. Ghonim et al18 showed that the level of IL17 
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does not increase in bronchoalveolar lavage fluid (BALF) 
of PARP1−/− mice but found an increase of this cytokine 
in PARP1-deficient CD4+ cells in vitro stimulated. In an 
inflammatory arthritis mouse model, Ahmad et al72 showed 
that IL17 levels decrease upon PARP pharmacological 
inhibition with 5-aminoisoquinolinone (5-AIQ). Because, as 
it will be discussed later, IL17 levels were affected also by 
PARP14, it is possible that the data obtained upon pharma-
cological inhibition do not reflect their selective dependence 
on the PARP1 enzyme. Actually, no conclusive data are 
available so far.
Several studies showed that PARP1 is involved in B cell 
differentiation and function, even though PARP1−/− mice 
display a normal number of B cell in the peripheral lymphatic 
organs.66,73 Somatic hypermutation and gene conversion, 
typical of B cell immunoglobulin (Ig) generation, require 
PARP1, which promotes mutagenic repair mechanisms 
through its breast cancer 1 C-terminal domain.74 The result 
obtained upon PARP1 lack or inhibition is an increased 
fidelity repair of Ig chains.74 PARP1 is also involved in 
Ig class switch recombination. Depending on the stimuli, 
B cells from PARP1 knockout or pharmacological inhibition 
increase the frequency of Ig class recombination to IgA and 
IgG1, whereas they decrease the switch to IgG2a.66
Underlying the anti-inflammatory effects of PARP1 inhi-
bition or deficiency in allergic inflammatory diseases, such as 
asthma, Datta et al75 reported a decrease in the amount of IL5 
mRNA with a consequent reduction of the number of eosino-
phils infiltrating the lungs in an allergen-induced mouse 
model. The molecular mechanism that occurs downstream 
the binding of IL4 to its receptor has been demonstrated: after 
allergen stimulation, the inhibition or the complete absence 
of PARP1 enzymatic activity causes a remarkable increase 
of STAT6 protein degradation carried out by calpain rather 
than the proteasome system. Thus, it leads to a reduction of 
the transcription factor GATA-binding protein 3 (GATA3) 
mRNA and of protein levels culminating in IL5 transcrip-
tional repression.75 Decreased levels of STAT6 were found 
in another study based on the pharmacological inhibition of 
PARP1 after a well-established inflammation, and in remod-
eling in a mouse model of airway disease, using house dust 
mite (HDM) as an allergen.76 These results have shown that 
PARP1 directly regulates STAT6 activation in an allergen 
stimulation-dependent fashion and that its inhibition can 
improve all signs of allergic inflammation.
Another PARP family protein, PARP14, was shown 
to be correlated with allergic airway diseases. PARP14 
regulates STAT6-dependent gene transcription acting as 
a transcriptional switch. Under nonstimulating conditions, 
PARP14 binds to the promoters and recruits histone deacety-
lase (HDAC) 2 and 3 repressing gene transcription. Upon IL4 
stimulation and STAT6 activation, the catalytic activity of 
PARP14 increases, resulting in ADP-ribosylation of HDACs 
that leave the GATA3 promoter, making this transcription 
factor active.77 Consequently, in allergic inflammation, 
pharmacologic inhibition or ablation of PARP14 expression 
results in a reduced STAT6-dependent gene transcription. 
PARP14 promotes Th2 differentiation, as naive T cells from 
PARP14−/− mice cultured under Th2 conditions showed a 
reduced production of Th2 cytokines (IL4, IL5, and IL13).78 
By using ChIP-Seq analysis, Riley et al79 identified 2,744 
genes whose expression in Th2 cells was dependent on the 
expression of PARP14. Therefore, this enzyme enhances 
the expression of Th2 genes as it represses the expression 
of Th1-associated genes.79 The ability of PARP14 to promote 
Th2 differentiation is ascribed to its capacity to regulate 
the activation of STAT6 and its binding to the GATA3 
promoter.78,80 It is noteworthy that PARP14-deficient animals 
showed reduced levels of IgE, which were correlated with 
the intrinsic role of PARP14 in Ig class switching to IgE.78 
PARP14−/− mice displayed a selective impairment in IgA 
production associated with a reduced marginal zone and 
increased follicular B cell numbers.81 Recently, the role of 
PARP14 in other T cell types was elucidated. T follicular 
helper (Tfh) cells secrete IL4, IL10, and IL21 and play an 
essential role in allergic responses for the germinal center 
formation of T cell-dependent antigens, as well as for the IgE 
production.82 PARP14 is highly expressed in Th17 cells, and 
PARP14 deficiency or the pharmacological inhibition of its 
activity result in a decreased Th17 differentiation in vitro and 
in a model of allergic airway inflammation.83 As a matter of 
fact, reduced IL-17A levels were detected in the BALF of 
PARP14-deficient mice in comparison with control mice.83 
According to the study by Riley et al,79 PARP14 regulates 
the expression of IL21, which in turn promotes Th17 and Tfh 
development and function. It is noteworthy that a number of 
genes were found to be dependent on the PARP14 activity 
but not regulated by STAT6, this latter feature suggesting 
that they play STAT6-independent functions.79 PARP14 
also promotes Tfh development through the activation of 
STAT3, which plays a pivotal role in the differentiation of 
both Tfh and Th17 cells. PARP14 ablation in mice showed 
a reduced number and frequency of Tfh in allergic airway 
inflammation model. Similarly, PARP14−/− T cells showed a 
decreased differentiation of Tfh and Th17 due to a decreased 
phosphorylation of STAT3.83
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Although the lack of PARP1 and PARP14 causes similar 
effects in terms of protection against airway inflammation, 
GATA3 gene expression, and Th2 differentiation, the two 
enzymes operate in different ways. When PARP1 is inhibited 
or absent, calpain mediates the degradation of STAT6 in the 
cell,75 whereas if PARP14 is absent, HDACs remain bound 
to the GATA3 promoter inhibiting its gene expression.77 
Furthermore, PARP14 affects the expression of IL17A, 
IL17F, and IL21,79,83 whereas the effects of PARP1 on IL17 
are unclear71 and probably not relevant. All these findings 
suggest that PARP1 and PARP14 are at a crossroad in the 
allergic airway disease pathway, working with distinct but 
overlapping mechanisms (Figure 1). Moreover, they also 
suggest that PARP enzymes play a significant role in allergic 
airway diseases.
PARP inhibition in asthma: 
evidences from preclinical studies
Experiments performed with PARPs inhibitors and knock-
out mice have shown that PARP enzymes are involved 
in several inflammatory diseases by triggering cell death 
in injured tissues.14,84 Havranek et al85 demonstrated an 
increased PARP1 expression and activation in an allergen-
induced airway inflammation model, which suggests a 
direct involvement of the enzyme in allergic inflammation. 
In this study, two murine models of allergic airway inflam-
mation, sensitization, and challenge to ovalbumin (OVA) 
and intratracheal exposure to IL13 were used to evaluate 
the PARP1 protein expression, localization, and activity, as 
well as inflammation and goblet cell hyperplasia. The authors 
concluded that PARP1 expression and activity are increased 
by allergen-activated inflammatory mediators. In contrast, 
PARP1 protein, or its activity, did not change after a single 
exposure to IL13, a condition under which goblet cells 
hyperplasia occurred without inflammation.85
From an immunological point of view, asthma is charac-
terized by a deregulated Th2 immune response,86 and the IL4-
activated STAT6 pathway is involved in the progression of the 
disease.87,88 The role of PARP14 and of its enzyme activity in 
asthma and Th2 differentiation were investigated by Mehrotra 
et al89 by using a murine model of asthma with OVA as aller-
gen in in vitro Th cell differentiation. Interestingly, PARP14 
was shown to act, as previously described, as a transcriptional 
switch for IL4-dependent STAT6-mediated transcription.89
Figure 1 Features of PARP knockout mice in asthma at a glance.
Notes: PARP1−/− and PARP14−/− knockout mice features. Some of them are common to both enzymes (gray-green area). PARP14−/− knockout mice show a more specific 
profile link to a proallergic role of this enzyme in inflammatory airway diseases. However, PARP1−/− ablation also shows protection in other models of diseases displaying a 
broader range of functions. *increased levels were found in T cells derived from PARP1−/− mice, whereas unchanged or decreased levels were observed in BALF of PARP1−/− 
mice after allergen challenge.18,65 °Data are referred to the frequency of immunoglobulin class recombination of B cell from PARP1−/− mice.66 #Zhang et al68 reported elevated 
levels of iL17 in PARP1−/− mice, and Ghonim et al18 in PARP1-deficient CD4+ cells in vitro stimulated. Nasta et al67 showed no change in iL17 levels, as well as Ghonim et al18 
in BALF of PARP1−/− mice. ↓, inhibition/downregulation; ↑, upregulation; ↔, no change.
Abbreviations: AHR, airway hyperresponsiveness; AP-1, activator protein-1; BALF, bronchoalveolar lavage fluid; CCL, chemokine (C–C motif) ligand; CD4+, cluster of 
differentiation 4+; iCAMs, intercellular cell adhesion molecules; iFN, interferon; iL, interleukin; iNOS, inducible nitric oxide synthase; iP-10, interferon-gamma-inducible 
protein 10; NF-AT, nuclear factor of activated T-cells; NF-κB, nuclear factor κB; PARP, poly(ADP-ribose) polymerase; STAT, signal transducer and activator of transcription; 
Tfh, T follicular helper; TNF, tumor necrosis factor; Treg, regulatory T cell.
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Historically, nicotinamide, a pleiotropic biological agent, 
can be considered to be the first PARPs inhibitor, and various 
studies of Bekier et al90,91 in the early 1970s provided the hints 
that PARPs could be involved in the pathogenesis of asthma. 
More recently, Boulares et al92 published a study focused 
on the role of PARPs activation in asthma. They showed 
the activation of PARPs through the immunohistochemi-
cal detection of PAR (the product of the PARP-catalyzed 
reaction) in a conventional murine model of asthma using 
OVA as allergen. The PARPs inhibitor used in this study 
was 3-aminobenzamide (3-ABA), and the authors found 
a reduced inflammatory cell migration and a suppressed 
expression of iNOS. Moreover, they confirmed these results 
in a PARP1-deficient mouse model in which protection 
from the OVA-induced lung inflammation was obtained.92 
Virag et al93 investigated the role of PARPs activation in 
asthma using a similar animal model, where the PARPs 
inhibitor was N-(6-Oxo-5,6-dihydrophenanthridin-2-yl)- 
(N,N-dimethylamino)acetamide hydrochloride (PJ-34). 
A reduced number of neutrophils, but not of eosinophils 
in the BALF, was observed in the single exposure model. 
However, the authors did not obtain a reduction in the severe 
inflammation protocol. Cytokines levels in BALF were 
detected, and PJ-34 suppressed the production of tumor 
necrosis factor (TNF) α, IL12, and the CCL3 but did not 
affect the expression of chemokine (C–X–C motif) ligand 
2 (CXCL2) or the production of IL5 and IL13.93 Later, a 
group from our laboratory investigated the role of PARPs 
activation in a guinea pig asthma model using OVA for 
sensitization.94 The PARPs inhibitors used were 3-ABA 
and 5-AIQ. Both inhibitors reduced the severity of cough 
and the occurrence of dyspnea. Moreover, they delayed the 
respiratory abnormalities. In this study, it was also shown 
that PARPs inhibitors are able to prevent the biochemical 
changes in lungs or BALF measured as myeloperoxidase 
activity, malondialdehyde formation, tyrosine nitration, 
serum nitrite levels, and TNFα production.94 Another study, 
carried out by the Boulares et al, showed that PARPs play a 
role in eosinophils recruitment into lungs. Administration of 
the PARPs inhibitor thieno[2,3-c]isoquinolin-5-one (TIQ-A) 
before allergen challenge resulted in the suppression of Th2 
cytokines, including IL4, IL5, and IL13. A suppression of 
the eosinophils infiltration with associated mucus production 
in lung airways was also observed, which suggests a specific 
effect on IL5.95
The studies described above were performed upon 
administering PARPs inhibitors only before the allergic 
sensitization or rechallenge. Naura et al96 performed a single 
injection of TIQ-A in mice, 1 or 6 hours after OVA challenge. 
Postallergen challenge administration of the drug resulted 
in the suppression of IL4, IL5, and IgE production and pre-
vented airway hyperresponsiveness to methacholine. IL13 
was reported to decrease significantly, causing the interrup-
tion of airway mucus secretion and goblet cell hyperplasia.96 
Nevertheless, the authors did not investigate the remodeling 
events typical of chronic asthma because they evaluated the 
effect of TIQ-A in an asthma acute model by focusing their 
attention on airway inflammation and hyperresponsiveness. 
This study documented that PARP inhibitors were active also 
after sensitization and challenge. The results suggested that 
PARP inhibitors could be administered within a reasonable 
time, ie, commensurate with the therapeutic approach against 
human asthma. More recently, Ghonim et al97 strengthened 
the validity of the postchallenge drug administration pro-
tocol using the OVA-based mouse model of asthma and 
primary CD4+ cells. In fact, they demonstrated that olaparib, 
administered 30 minutes after challenge, blocks asthma-like 
manifestations (inflammation and hyperresponsiveness) by 
modulating CD4+ cells without prominent effects on B cells 
function. The protective effects of olaparib were ascribed to 
the suppression of Th2 cytokines, such as CCL11, IL4, IL5, 
IL6, IL13, and macrophage colony-stimulating factor.97
The hallmark features of asthma include airway eosino-
philic inflammation and structural remodeling characterized 
by increased thickness of the subepithelial reticular basement 
membrane. This latter event goes along with peribronchial 
collagen deposition, increased airway smooth muscle 
mass, goblet cell hyperplasia, and angiogenesis, which 
are associated with a progressive and irreversible loss of 
lung function.97 These structural changes are present even 
in mild asthma and are permanent, albeit symptoms may 
remit for some time.98,99 Recent data showed that remodeling 
could be independent of inflammation. For example, it was 
reported that both eosinophilic and noneosinophilic patients 
appear equally responsive to salbutamol, although asthmatic 
noneosinophilic subjects do not benefit from corticosteroid 
treatment. This suggests that remodeling could be present 
in both groups.100
The first evidence that PARP inhibition affects the airway 
remodeling in asthma was given by Lucarini et al101 who showed 
that PARP inhibition reduced airway damage and remodel-
ing in guinea pigs using hydroxyl-dimethylaminomethyl- 
thieno[2,3-c]isoquinolin-5(4H)-one (HYDAMTIQ), a 
potent and selective PARP1 and PARP2 inhibitor, that was 
previously tested in stroke-induced inflammation and brain 
damage. A limitation of this study is represented by the 
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asthma model, OVA in this case, which is not specifically 
designed to evaluate all the aspects of airway remodeling. 
As a matter of fact, animal models, with the use of HDM 
instead of OVA as allergen, better reproduce the remodeling 
process, in addition to inflammation, occurring in humans 
affected by asthma.102 Recently, our group and others used 
a nonconventional mouse model of chronic asthma with 
HDM as an allergen to investigate the PARP inhibition 
on inflammation and remodeling.18,76 This protocol led to 
sustained airway eosinophilic inflammation associated with 
immune activation in the lung, allergen-specific memory 
response by splenocytes, and humoral immunity to HDM.103 
Differently from OVA, which is an innocuous protein, the 
HDM extract belongs to environmental antigens and causes 
cytotoxicity measured as increased lung levels of oxidative 
damage to proteins, lipids, and nucleic acids.104 Recently, 
Ghonim et al18 demonstrated that the inhibition of PARP1 
and PARP2 obtained by olaparib is effective in blocking 
established HDM-induced diseases in mice, including airway 
eosinophilia and hyperresponsiveness. These effects are 
linked to a marked reduction in Th2 cytokines production 
and are related to a modulation of CD4+ T cells function 
as well as to an increase in Treg cells.18 In our work,76 the 
postallergen challenge PARP inhibition and the 5-week 
long protocol of HDM administration reflect more closely 
the pathological modification occurring in human asthma 
and its therapeutic approach. As expected, this experimen-
tal model elicits a strong chronic inflammatory response in 
mice, characterized by systemic Th2 immunity and airway 
remodeling. Our results are in line with previous studies 
concerning the protective effect carried out on inflamma-
tion by PARP inhibition: we obtained a robust decrease in 
airway inflammation, although we did not find a decrease 
of the IgE level, as well as of IgG1 and IgG2a titers. In our 
study, we found a small difference between acute and chronic 
models (10 days versus 5 weeks) in terms of cells number 
in the BALF. Therefore, PARP inhibition was a little more 
effective in the acute model possibly because of the induction 
of a small inflammation level. The results registered can be 
ascribed to a downregulation of STAT6 DNA binding, and, 
partly, to a decrease in the mRNA level of CCL11. It is worth 
mentioning that these inhibitory treatments did not affect the 
NF-kB DNA-binding activity, although we cannot rule out 
the possibility that they inhibit the NF-kB transcriptional 
capacity by removing the PARP1-NF-kB protein–protein 
interaction.76 Moreover, PARP inhibition by 5-AIQ and 
3-ABA clearly induced a reduction of goblet cell hyperplasia. 
Instead, subepithelial collagen deposition was reduced only 
by 5-AIQ, while both inhibitors were ineffective against 
α-smooth actin lung deposition. Thus, the mentioned late 
events, typical of the remodeling process, were affected by 
5-AIQ better than by 3-ABA.76
In in vivo studies of asthma, several PARPs inhibitors 
have been used, and it should be noticed that their activity 
includes inhibiting more than one member of the PARP family 
(Table 1). Consequently, the beneficial effects observed 
can be ascribed to the synergistic activity, because 5-AIQ 
targets PARP1, 2, and 3; PJ-34 targets PARP1, 2, and 14; 
HYDAMTIQ targets PARP1 and 2; olaparib targets PARP1, 
2, 3, and 4; and TIQ-A targets PARP1 and 3 (Table 1).105 
Table 1 PARPs inhibitors and their selectivity for the catalytic 
domain of different members of PARP family
PARPs inhibitors Selectivity References
? ???
???
3-ABA
weak, unselective 
inhibitor except 
PARP3+
wahlberg et al105
???
??
?
5-AiQ
PARP1++
PARP2++
PARP3++
wahlberg et al105
?? ??
?? ?
PJ-34
PARP1, 2+++
PARP3++
PARP4+
PARP14, 16+
wahlberg et al105
??
?
?
TiQ-A
PARP1, 3++
PARP2, 4, 10, 14, 15+
wahlberg et al105
??
?
?
?
??
HYDAMTIQ
Potent and selective 
PARP1, 2 
Lucarini et al101
? ?? ? ?
?
? ?
?
Olaparib
PARP1, 2, 3++++
PARP4+++
PARP12, 15, 16+
wahlberg et al105
Notes: The selectivity of several PARPs inhibitors for human PARPs catalytic 
domain was assessed by DSF. in general, PARP1–4 selective inhibitors have a higher 
molecular weight and low cLogP values, and they are hydrophilic by exposing an 
extended polar surface area. On the contrary, unselective PARPs inhibitors are the 
smaller molecules, with less polar surface area. The selectivity scale is arbitrarily 
based on the heat map.105 Two distinct mechanisms of action have been proposed 
for these drugs: 1) a competitive enzyme inhibition action and 2) a PARP trapping 
mechanism, which might have a relevant role in PARPs inhibition.3 in vivo, other 
factors such as different levels of proteins expression, abundance of substrates, and 
metabolism, to name a few, may influence the activity of PARPs inhibitors.
Abbreviations: 3-ABA, 3-aminobenzamide; 5-AiQ, 5-aminoisoquinolinone; DSF, 
differential scanning fluorimetry; HYDAMTIQ, hydroxyl-dimethylaminomethyl-
thieno[2,3-c]isoquinolin-5(4H)-one; PARP, poly(ADP-ribose) polymerase; PJ-34, 
N-(6-Oxo-5,6-dihydrophenanthridin-2-yl)-(N,N-dimethylamino)acetamide hydro-
chloride; TiQ-A, thieno[2,3-c]isoquinolin-5-one.
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Thus, the different findings emerging from many studies can 
be ascribable to the affection of different PARP isoforms in 
addition to the particular animal model used.
In summary, the attenuation of lung injury, the improve-
ment of respiratory abnormalities, and the provocation of 
the anti-inflammatory effect have been obtained in several 
animal models using different OVA or HDM allergens, upon 
PARP1/14 deletion (Figure 1) or pharmacological inhibition 
(Table 2). These effects occurred even when drugs were 
administered after the antigen challenge. To identify novel 
therapeutic approach(es) to target human asthma, especially 
airway remodeling, the use of preclinical models that truly 
reflect the features of the human disease is essential.
Conclusion and perspectives
PARP enzymes play a pivotal role in both inflammation and 
remodeling and in the consecutive airway function, such as 
airway hyperresponsiveness, as it has been observed in the 
preclinical studies reported.
Until recently, it was thought that chronic inflammation 
might drive remodeling. However, it is now definitely clear 
that inflammation and remodeling are two distinct processes, 
Table 2 effects of PARPs inhibition in asthma models
Mode of PARP inhibition In vivo models Findings References
3-ABA, 20 mg/kg
Preallergen challenge
Mice C57BL/6
OvA
↓Inflammatory cell infiltration (BALF/lung)
↓iNOS expression (lung)
↔igG (serum)
Boulares et al92
PJ-34, 10 mg/kg
Preallergen challenge
Mice Balb/c
OvA
↓Neutrophils ↔eosinophils (BALF)
↓Myeloperoxidase activity
↓MiP-2, TNFα, iL12 expression (lung)
virag et al93
3-ABA, 10 mg/kg
5-AiQ, 0.5 mg/kg
Preallergen challenge
Guinea pigs
OvA
↓Severity of cough/dyspnea
↓AHR
↓MPO activity
↓MDA formation
↓Tyrosine nitration (lung)
↓TNFα (BALF)
↓Nitrite level (BALF)
Suzuki et al94
TiQ-A, 6 mg/kg
Preallergen challenge
Mice C57BL/6
OvA
↓Inflammatory cell infiltration
↓ige (BALF)
↓iL4, iL13, iL5, iL10, GM-CSF (lung)
↓Mucus production (goblet cells)
Oumouna 
et al95
TiQ-A, 6 mg/kg
Preallergen and postallergen 
challenge
Mice C57BL/6
OvA
↓AHR
↓iL4, iL5, iL13
↓ige (BALF)
↓Mucus production (goblet cells)
Naura et al96
PJ-34
During sensitization phase, 
during allergen challenge, 
and during both challenge 
and sensitization
Mice Balb/c and 
C57BL/6
OvA
↓AHR
↓Inflammatory cell infiltration
↓ige (BALF)
↓ige (serum)
↓iL4, iL5, iL13
↓CCL11, CCL17, CCL24
↓eosinophils, T cells (lung)
↓Mucus secretion (goblet cells) ↓iL4, iL5, iL13
↑iFNγ (splenocytes)
Mehrotra 
et al78
HYDAMTIQ, 1–10 mg/kg
Preallergen challenge
Guinea pigs
OvA
↓AHR
↓Appearance and severity of cough
↓Hystamine release (mast cells)
↓TNFα, iL1β, iL5, iL6, iL18 (lung) ↓PGD2 (BALF)
↓MDA, 8-OHdG
↓eMBP, MPO activity (lung)
↑MnSOD (lung)
↓Collagen deposition
↓Smooth muscle layer thickness
↓Goblet cell hyperplasia
Lucarini et al101
(Continued)
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Table 2 (Continued)
Mode of PARP inhibition In vivo models Findings References
Olaparib, 1–10 mg/kg
Postallergen challenge
Mice C57BL/6J
OvA
↓Airway cell migration
↓AHR
↓Mucus production (goblet cells)
↓CCL11, iL4, iL5, iL6, iL13, M-CSF
↔iFNγ (BALF)
↓ige (BALF/serum)
↓CD4+ T cells
↑Treg cells (spleen)
Ghonim et al97  
(CD4+ cells)
Olaparib, 5 mg/kg
Preallergen challenge
Mice C57BL/6
HDM
↓AHR
↓Overall cellularity in lungs
↓CCL11, iL4, iL5, iL13, iL2, iP-10 (BALF)
↔iFNγ, iL10, iL17 (BALF)
↔CD4+ T cells
↓Spleen weight, overall number of cells
↑iL17 (serum)
Ghonim et al18
3-ABA, 40 mg/kg
5-AiQ, 0.5 mg/kg
Postallergen challenge
Mice Balb/c
HDM
↓Inflammatory cell migration (BALF/lung)
↓STAT6
↓CCL11 (lung)
↓Collagen deposition ↓goblet cells hyperplasia
↔Airway smooth muscle layer thickness
↔ige, igG1, igG2a (serum) ↔iL4, iL5, iL13 
(splenocytes)
Zaffini et al76
Note: The results obtained on several asthma models with different PARPs inhibitors are summarized.
Abbreviations: 3-ABA, 3-aminobenzamide; AHR, airway hyperresponsiveness; 5-AIQ, 5-aminoisoquinolinone; BALF, bronchoalveolar lavage fluid; CCL, chemokine 
(C–C motif) ligand; CD4+, cluster of differentiation 4+; eMBP, eosinophilic major basic protein; GM-CSF, Granulocyte-macrophage colony-stimulating factor; HDM, house 
dust mite; HYDAMTIQ, hydroxyl-dimethylaminomethyl-thieno[2,3-c]isoquinolin-5(4H)-one; IFN, interferon; IL, interleukin; iNOS, inducible nitric oxide synthase; IP-
10, interferon-gamma-inducible protein 10; M-CSF, macrophage colony-stimulating factor; MDA, malondialdehyde; MIP-2, macrophage inflammatory protein-2; MnSOD, 
manganese superoxide dismutase activity; MPO, myeloperoxidase activity; OVA, ovalbumin; 8-OHdG, 8-OH-2′-deoxyguanosine; PGD2, prostaglandin D2; PJ-34, N-(6-Oxo-
5,6-dihydrophenanthridin-2-yl)-(N,N-dimethylamino)acetamide hydrochloride; STAT6, signal transducer and activator of transcription 6; TiQ-A, thieno[2,3-c]isoquinolin-5-
one; TNF, tumor necrosis factor.
requiring different biochemical pathways and occurring in 
a parallel manner and not in a sequential manner.102 The 
current main approaches to asthma management are essen-
tially based on the inflammatory parameters and not on 
remodeling and consequent airway hyperresponsiveness. 
Although novel therapeutic approaches (mainly the use of 
monoclonal antibody to IgE and Th2 cytokines, such as IL5 
and IL13) have improved the control of the disease, they 
do not result in disease modification, or it seems that they 
can be applied only to a subgroup of patients.106–108 In fact, 
we are able to reduce exacerbations by targeting eosino-
philic inflammation, but novel approaches and targets are 
required to impact on lung function.109 On the other hand, 
PARPs sustain the expression of cytokines, chemokines, 
and inflammatory mediators, such as TNFα, IL1, IL6, and 
iNOS. These mediators are also involved in the expression 
of several adhesion molecules, such as P-selectin, E-selectin, 
mucosal address in cell adhesion molecule 1, IL8, CCL2, 
CCL3, CXCL2, metalloproteinase 9. They usually partici-
pate in a plethora of stress signaling pathways.110 As many 
experimental results have shown, the inhibition or deletion 
of PARPs causes protective effects in acute and chronic 
airway diseases, which are mainly due to the inhibition of 
cell migration. Anyway, the link among PARPs, airway 
remodeling, and key factors related to the disease persistence 
require further investigations, even if the first evidences are 
promising (Table 2). Although in our study we registered 
variable effects of two PARP inhibitors used, the decrease 
in hallmark of airway remodeling observed in experiments 
performed by our and another group76,101 could lead to a 
step change in asthma therapy. Indeed, the weak point of 
preclinical studies reported here is the use of PARP inhibi-
tors displaying a promiscuous ligand activity. In fact, it is 
possible that the effects observed are the result of a syner-
gistic inhibition of many PARP enzymes (Table 1). Further 
investigations should be addressed to the role of each PARP 
enzyme in the airway remodeling process to elucidate which 
are the most active PARP isoform(s) in this irreversible 
process. Particularly, the connections existing among airway 
remodeling in asthma, TGFβ, NF-kB, and PARPs should be 
explored in detail.
Discrimination between the different effects of PARPs 
inhibitors in acute and chronic asthma could be an interesting 
purpose. However, in this review, an exhaustive comparison 
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among the studies reported is impossible because they follow 
too different experimental designs.
PARPs inhibitors are known to be active as anti-
inflammatory agents, and they are already used in several 
pathologies: neurodegeneration, myocardial infarction, 
arthritis, colitis, and other nononcological diseases.14 The 
main concern on the therapeutic use of PARPs inhibitors in 
nononcological diseases is due to the wide expression and 
function of PARPs in physiological key processes, such 
as metabolism regulation, aging, circadian rhythms, viral 
infections, and mitochondrial homeostasis to name a few,110 
with unpredictable side effects especially for a long-time 
therapy. Therefore, it would be extremely important in this 
case to target, finding more selective inhibitors, only the 
PARP isoforms that are involved in the disease. Nonethe-
less, it is noteworthy that asthma allows an inhaled therapy, 
which can limit the side effects of drugs especially if they 
are administrated at low doses.
Therefore, a future multimechanistic approach to asthma, 
including PARPs inhibitors, may lead to a more efficacious 
management of this disease.
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